(Q34975842)

5 August 2017

1 reference

title

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence (English)

1 reference

5 August 2017

0 references

2

Gillian M Keating

1 reference

5 August 2017

Jennifer S Orman

1

1 reference

5 August 2017

language of work or name

1 reference

1 January 2009

1 reference

5 August 2017

1 reference

5 August 2017

volume

69

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

577-607

1 reference

Buprenorphine: a potential new treatment option for opioid dependence

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969050-00006

Diversion of methadone: illicit methadone use among applicants to two metropolitan drug abuse programs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969050-00006

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969050-00006

Clinical pharmacology of buprenorphine: ceiling effects at high doses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969050-00006

Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969050-00006

Nasal administration of naloxone is as effective as the intravenous route in opiate addicts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969050-00006

Comparison of buprenorphine and methadone in the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969050-00006

Three methods of opioid detoxification in a primary care setting. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200969050-00006

Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans

21 January 2018

1 reference

12 December 2020

A controlled trial of buprenorphine treatment for opioid dependence

1 reference

12 December 2020

Buprenorphine and naloxone interactions in opiate-dependent volunteers*

1 reference

12 December 2020

Buprenorphine: how to use it right

1 reference

12 December 2020

Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone

1 reference

12 December 2020

Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts

1 reference

12 December 2020

Effects of buprenorphine and methadone in methadone-maintained subjects.

1 reference

12 December 2020

Pharmacologic treatments for opioid dependence: detoxification and maintenance options

1 reference

12 December 2020

Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence

1 reference

12 December 2020

A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone).

1 reference

12 December 2020

Medication development for addictive disorders: the state of the science

1 reference

12 December 2020

Buprenorphine tapering schedule and illicit opioid use.

1 reference

12 December 2020

Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis

1 reference

12 December 2020

Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet

1 reference

12 December 2020

Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine

1 reference

12 December 2020

Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine

1 reference

12 December 2020

Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen

1 reference

12 December 2020

Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation

1 reference

12 December 2020

Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment

1 reference

12 December 2020

Buprenorphine and naloxone interactions in methadone maintenance patients

1 reference

12 December 2020

Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study

1 reference

12 December 2020

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

1 reference

12 December 2020

Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial

1 reference

12 December 2020

Buprenorphine for the management of opioid withdrawal

1 reference

12 December 2020

A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.

1 reference

12 December 2020

Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality

1 reference

12 December 2020

Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings

1 reference

12 December 2020

A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence

1 reference

12 December 2020

Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients

1 reference

12 December 2020

Buprenorphine treatment in an urban community health center: what to expect

1 reference

12 December 2020

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

1 reference

12 December 2020

Treatment of adolescent opioid dependence: no quick fix.

1 reference

12 December 2020

Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.

1 reference

12 December 2020

Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers

1 reference

12 December 2020

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Using buprenorphine short-term taper to facilitate early treatment engagement

1 reference

12 December 2020

A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids

1 reference

12 December 2020

Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients

1 reference

12 December 2020

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers

1 reference

12 December 2020

Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans

1 reference

12 December 2020

Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence

1 reference

12 December 2020

QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial

1 reference

12 December 2020

Office-based buprenorphine treatment for opioid-dependent patients

1 reference

12 December 2020

Pharmacokinetics of the combination tablet of buprenorphine and naloxone

1 reference

12 December 2020

Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone

1 reference

12 December 2020

Diffusion of substance abuse treatment: will buprenorphine be a success?

1 reference

12 December 2020

Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients

1 reference

12 December 2020

Less pain, more gain: buprenorphine-naloxone and patient retention in treatment

1 reference

12 December 2020

Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment

1 reference

12 December 2020

Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine

1 reference

12 December 2020

The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand

1 reference

12 December 2020

Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial

1 reference

12 December 2020

Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome

1 reference

12 December 2020

Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients.

1 reference

12 December 2020

Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting

1 reference

12 December 2020

Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study

1 reference

12 December 2020

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network

1 reference

12 December 2020

Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period

1 reference

12 December 2020

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

1 reference

12 December 2020

A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers

1 reference

12 December 2020

Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans

1 reference

12 December 2020

A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.

1 reference

12 December 2020

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

1 reference

12 December 2020

A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials

1 reference

12 December 2020

Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences

1 reference

12 December 2020

A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence.

1 reference

12 December 2020

Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls

1 reference

12 December 2020

Effects of high-dose intravenous buprenorphine in experienced opioid abusers

1 reference

12 December 2020

Abuse liability assessment of buprenorphine-naloxone combinations.

1 reference

12 December 2020

Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S.

1 reference

12 December 2020

Buprenorphine alone and in combination with naloxone in non-dependent humans.

1 reference

12 December 2020

Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years

1 reference

12 December 2020

Buprenorphine-containing treatments: place in the management of opioid addiction

1 reference

12 December 2020

The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?

1 reference

12 December 2020

Buprenorphine and naloxone alone and in combination in opioid-dependent humans

1 reference

12 December 2020

A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence

1 reference

12 December 2020

Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence

1 reference

12 December 2020

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience

1 reference

12 December 2020

Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing

1 reference

12 December 2020

Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine

1 reference

12 December 2020

Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence

1 reference

12 December 2020

Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence

1 reference

12 December 2020

Effects of buprenorphine/naloxone in opioid-dependent humans

1 reference

12 December 2020

Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir

1 reference

12 December 2020

Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors

1 reference

12 December 2020

10.2165/00003495-200969050-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1024461760

0 references

1 reference